Emyria's Michel Winlo speaks with Proactive after reporting positive Phase 1 trial data for EMD-RX5 indicating ideal bioavailability, safety and tolerability among 12 healthy and demographically diverse volunteer subjects. He says compared to Epidyolex, which is the sole CBD-only medicine registered with the TGA and FDA, EMD-RX5 provides equivalent total drug exposures over 24 hours with a more predictable and sustained drug release.
Emyria welcomes positive Phase 1 trial data for EMD-RX5
